PR Newswire Clinical TrialsOriginal article
Lutris Pharma to Present Updated Data from Its Phase 2 Trial of LUT014 Gel for the Treatment of Patients With EGFRI-Induced Acneiform Rash at the EADV Congress
Phase 2LUT014 GelPositive
AI Analysis
Summary
Lutris Pharma announced the presentation of updated Phase 2 trial data for LUT014 Gel, a treatment for EGFRI-induced acneiform rash, at the EADV Congress. The company focuses on mitigating dermatological toxicities associated with anti-cancer therapies.
Clinical Trial Data
Phase
Phase 2
Outcome Details
Updated data presentation
Importance:5/10
Sentiment:
0.50
Phase 2Data PresentationDermatological ToxicityEADV CongressClinical Stage
Read the original article
Published by PR Newswire Clinical Trials on September 16, 2026 11:03 AM